1418 related articles for article (PubMed ID: 18419876)
1. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
2. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
Friedman H; Song X; Crespi S; Navaratnam P
Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
[TBL] [Abstract][Full Text] [Related]
4. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
5. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
6. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.
Keating KN; Friedman HS; Perfetto EM
Curr Med Res Opin; 2006 Feb; 22(2):327-33. PubMed ID: 16466604
[TBL] [Abstract][Full Text] [Related]
8. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Lloyd A; Holman A; Evers T
Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia.
Davis SL; Delgado G; McKinnon PS
Clin Infect Dis; 2005 Jul; 41 Suppl 2():S136-43. PubMed ID: 15942880
[TBL] [Abstract][Full Text] [Related]
10. In-hospital observation after antibiotic switch in pneumonia: a national evaluation.
Nathan RV; Rhew DC; Murray C; Bratzler DW; Houck PM; Weingarten SR
Am J Med; 2006 Jun; 119(6):512.e1-7. PubMed ID: 16750965
[TBL] [Abstract][Full Text] [Related]
11. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
File TM; Milkovich G; Tennenberg AM; Xiang JX; Khashab MM; Zadeikis N
Curr Med Res Opin; 2004 Sep; 20(9):1473-81. PubMed ID: 15383197
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
14. Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
Wenisch C; Krause R; Széll M; Laferl H
Infection; 2006 Aug; 34(4):190-5. PubMed ID: 16896576
[TBL] [Abstract][Full Text] [Related]
15. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
Shorr AF; Khashab MM; Xiang JX; Tennenberg AM; Kahn JB
Respir Med; 2006 Dec; 100(12):2129-36. PubMed ID: 16730170
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Morganroth J; Dimarco JP; Anzueto A; Niederman MS; Choudhri S;
Chest; 2005 Nov; 128(5):3398-406. PubMed ID: 16304291
[TBL] [Abstract][Full Text] [Related]
17. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.
Lin TY; Lin SM; Chen HC; Wang CJ; Wang YM; Chang ML; Wang CH; Liu CY; Lin HC; Yu CT; Hsieh LL; Kuo HP; Huang CD
Chang Gung Med J; 2007; 30(4):321-32. PubMed ID: 17939262
[TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Martin M; Moore L; Quilici S; Decramer M; Simoens S
Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
[TBL] [Abstract][Full Text] [Related]
19. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
[TBL] [Abstract][Full Text] [Related]
20. [Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization].
Geijo Martínez MP; Díaz de Tuesta Chow-Quan AM; Herranz CR; Gómez Criado C; Dimas Nuñez JF; Saiz García F
An Med Interna; 2002 Dec; 19(12):621-5. PubMed ID: 12593029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
